Qiming Leads $29M Round In Chinese Antibody Drug Developer Sino Biological

Login to View

China-focused venture capital firm Qiming Venture Partners has led a RMB200 million (US$29 million) series A round in Sino Biological Inc., a Beijing-based recombinant protein and antibody developer, according to a company announcement.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in